The scientific reasoning for exploring GLP-1RAs in Parkinson’s disease is similarly strong, as PD is characterized by deficits in insulin/IGF-1 signaling, mitochondrial dysfunction, neuroinflammation, and the toxic accumulation of α-synuclein. This evidence concerns the gene IGF1 and Parkinson disease.